Skip to main content
. 2014 Jul 3;29(7):527–537. doi: 10.1007/s10654-014-9917-0

Table 2.

Campylobacteriosis in Switzerland: reported duration of illness, signs and symptoms, perceived severity, medical treatment and medication, December 2012–February 2013

n (%) or median (range)
(N = 159)
Campylobacter-associated morbidity
Duration of illness (days)a 7 (2.5–33)
No recovery by the time of the interview 43 (27.0)
Perceived severity of illnessb 8 (2–10)
Symptoms c
Diarrhoea 156 (98.1)
Abdominal pain 128 (80.5)
Fever 105 (66.0)
Nausea 70 (44.0)
Vomiting 54 (34.0)
Headache 20 (12.6)
Help seeking behaviour
Health care seeking before consulting a physicianc
 None: immediate consultation of a physician 52 (32.7)
 Pharmacy 31 (19.5)
 Medical hotline 8 (5.0)
 Friends and family 68 (42.8)
 Internet 23 (14.5)
 Health guide 8 (5.0)
 Other 10 (6.3)
Medical care seeking
 General practitioner (GP) 100 (62.9)
 Emergency department 23 (14.5)
 Emergency practice 19 (11.9)
 Paediatrician 6 (3.8)
 Medical specialist 4 (2.5)
 Other 7 (4.4)
Reasons for medical care seekingc
 Severe symptoms 105 (66.0)
 No amelioration 70 (44.0)
 Need of a medical certificate 6 (3.8)
 Other 44 (27.7)
Hospitalisation
Total 23 (14.5)
Malesd 13 (15.9)
Femalese 10 (13.0)
Number of nights in hospital 3 (1–13)
Medication
Consumed drugs 158 (99.4)
Drug classesc
 Antibiotic (Fluoroquinolones, Macrolides) 98 (61.6)
 Antidiarrhoeal (Loperamide, Charcoal) 84 (52.8)
 Probiotic (enterococci, saccharomyces) 73 (45.9)
 Analgesic (Acetaminophen, Dipyrone, NSAIDs) 66 (41.5)
 Antiemetic (Domperidone, Metoclopramide, Meclozine) 17 (10.7)
 Spasmolytics (Butylscopolamine) 17 (10.7)
 Acid blockers (Proton pump inhibitors) 5 (3.1)
Parenteral rehydration and/or drug application 38 (23.9)

aOnly those recovered at time of interview included (n = 116)

bN = 158

cMultiple answers possible

dN = 82

eN = 77